L’Oréal patents hair loss prognosis, diagnosis and treatment methods for alopecia

Writing in its international patent​​, L’Oréal said it had developed a method for the in vitro​ prognosis and/or diagnosis of a “common alopecic state of the scalp”​ by measuring the expression level of very specific genes* involved in the intercellular junctions of the scalp and/or hair follicle. It also outlined an in vitro​ method to evaluate the efficacy of treating a common alopecic state, including testing cosmetic treatments like hair lotions, gels, shampoos and conditioners made using gene modulators and certain active compounds.

*Genes identified by L’Oréal: CDH1, ACTB, ACTBL2, TUBB, TUBB2A, GSN, MY03B, MY05B, MY06, DSG2, DSG3, DSG4, DSC2, GJB2, GJA1, GJB6, GJA3, TJP2, CLDN8, CLDN10, CLDN19, and optionally CTNNB1 and CTNND2

L’Oréal said the prognosis, diagnosis and treatment methods specifically related to common alopecia caused by disruptions of the hair cycle, as opposed to immune alopecias like alopecia areata or spot baldness, alopecia universalis and alopecia totalis. Assessment and treatment could therefore be used for the likes of androgenetic alopecia, traction alopecia, female pattern hair loss, cicatricial alopecia, chemotherapy-induced or radiotherapy-induced alopecia, telogen effluvium, stress-related alopecia, seasonal alopecia, age-related alopecia and micro-inflammatory alopecia.

Understanding substantial temporary or definitive hair loss

“The natural hair loss of the hair can be estimated, on average, at a few hundred hairs per day for a normal physiological state,”​ the company wrote in its patent filing. “This constant physical renewal process undergoes a natural change during the course of ageing: the hairs become finer and their cycles shorter. Various causes may however bring about substantial temporary or definitive hair loss,”​ L’Oréal wrote in its patent filing.

.

Leave a Reply

Your email address will not be published.